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ABSTRACT 
   Breast cancer within incident of one million new cases each year has become one of the most common 
malignancies and leading cause of death among females. This disease is comprised of about 18% of 
women cancers. The availability of early detection and improved treatments may decrease the mortality 
rates which reflected in the United States and many other western countries. Breast cancer in over the 
past 20 years may also have contributed to the Increasing age, nulliparity, positive family history of 
breast cancer, and use of menopausal hormone therapy were positively risk factors associated with breast 
cancer. Therefore, studying this malignity is prominent due to its mortality world wild. Evaluation and 
study of different aspects of breast cancer have been established during past decays which, in this 
review, it is presented and discussed.  
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INTRODUCTION 
   Breast cancer, the most widespread malignant 
disease between women in Western countries, 
has poor prognosis following metastasis [1]. 
Breast cancer emerges when an unregulated 
growing of abnormal cells in different parts of 
breast tissue begins. This may develops in milk 
ducts and glands of breast. There are two main 
types of breast cancer: ductal carcinoma and 
Lobular carcinoma. In rare cases, breast cancer 
can start in other areas of the breast [2]. 
Normally the highest rate is found in the 
typically ‗westernized‘ countries of North 
America and Europe, while much lower rates 
are observed in Asian and African population  
[3]. According to recent statistics published by 
the American Cancer Society, 89% and 82% of 
women diagnosed with invasive breast cancer in 
the United States will still be alive 5 and 10 
years after diagnosis, respectively [4]. The rate 
of breast cancer epidemics in United Kingdom 
has its highest score within two per 1000 
women in their fifties which are the most 
capable of this type of cancer [5]. Generally low 
breast cancer incidence in Asian women has 
been reported [6]. Breast cancer occurrence is 
high in adolescence with the age of 40 to 50 
which are the most adequate. Although, many 
studies have been conducted, patient-age-
dependent differences in the biology and 
clinical outcomes of breast cancer have still not 
been definitively specified. Some younger 
women (mostly those 35 years old) have a more 
aggressive form of the disease characterized by 
larger, higher-grade tumors with vascular 
invasion, increased rate of aneuploidy, and 
higher S-phase fractions (SPFs) [7]. There are 
lots of risk factors associated with the cause of 
breast cancer development such as age, life 
style, obesity, family background, race, estrogen 
hormone as the therapeutic agent, reproductive 
factors( age of pregnancy, marriage and breast 
feeding), genetic mutations in BRCA1 and 
BRCA2 and other genetic factors [8-10]. In this 
review, different aspects of breast cancer have 
been studied. 
Breast Cancer Epidemiology 
Breast cancer is the most leading cause of 
cancer related -death in women in the world, 
with an estimated 1.4 million new breast cancer 
cases and 458,000 deaths in 2008 [11].The 
incident and morality rates of breast cancer vary 
internationally by more than 5-fold and it is 
very high in civilized populations. Generally, 
 




the highest incidence rates are found in 
Switzerland, U.S. whites, Italy, and many other 
European countries, whereas low rates are 
found in Africa, Asia, and South America. The 
rates in U.S. Hispanics and Asians are 
substantially higher compared with the rates in 
most cancer registries in Asia and Latin 
America. Regional patterns in mortality rates 
are generally similar to the incidence patterns, 
although U.S. whites, Hispanics, and Asian-
Pacific Islanders and Australia have relatively 
low rates, whereas U.S. blacks and Trinidad and 
Tobago have the highest rates. 
The high breast cancer incidence rates in white 
women in the United States and in most 
European countries reflect the long-standing 
high prevalence of reproductive factors 
associated with increased risk of breast cancer, 
including early menarche, late child bearing, 
fewer pregnancies, use of menopausal hormone 
therapy, as well as increased detection through 
mammography [12, 13]. Beside these factors, 
the high breast cancer epidemiology is in Israel 
may reflect the disproportionately high 
prevalence of BRCA1 and BRCA2 mutations in 
the Ashkenazi Jewish population. The lifetime 
risk of being diagnosed with breast cancer in 
women with BRCA1 or BRCA2 mutation is 
about 50% [14], compared with 13% in all U.S. 
women [15]. The relatively low mortality rates 
in the United States and many other western 
countries reflect the availability of early 
detection and improved treatments. Breast 
cancer incidence rates in the United States have 
decreased since the early 2000s largely due to 
reduction in the use of menopausal hormone 
therapy [16-18]; decreases in utilization of 
mammography [19] or decreases in the number 
of preclinical cases found by screening over the 
past 20 years may also have contributed to the 
decrease in the incidence rates [20, 21].In Iran, 
it is one of the most frequent malignancies 
among women and ranks the second most 
common cancer [22, 23].  
Breast Cancer Classification 
Breast cancer is divers due to its morphology 
and histology. Each of these aspects influences 
treatment response and prognosis. It can begin 
in different areas of the breast; the ducts, the 
lobules, or in some cases, the tissue in between 
[24]. As it is mentioned above there are 
different types of breast cancer that, two main 
category of breast cancer are as below: 
 Ductal carcinoma starts in the tubes (ducts) 
that move milk from the breast to the nipple. 
Most breast cancers are of this type. 
 Lobular carcinoma starts in the parts of the 
breast, called lobules that produce milk.  
In rare cases, breast cancer can start in other 
areas of the breast [2]. Breast cancer can be 
invasive or noninvasive. Invasive means it can 
spread through milk duct and lobules to other 
tissues. Invasive means it has not yet spread to 
other breast tissue. Noninvasive breast cancer is 
called ―in situ‖. 
 Ductal carcinoma in situ (DCIS), or 
intraductal carcinoma, is breast cancer in the 
lining of the milk ducts that has not yet invaded 
nearby tissues. It may progress to invasive 
cancer if untreated. 
 Lobular carcinoma in situ (LCIS) is a marker 
for an increased risk of invasive cancer in the 
same or both breasts [25]. 
Risk Factors 
There are lots of risk factors associated with 
breast cancer (see table 1). Family history is one 
of them; it is known to be one of the prominent 
risk factors for this malignancy. For instance, 
meta-analysis of familial breast cancer studies 
gives lifetime risk ratios of 1.80 in families with 
one affected first-degree relative, 2.93 in 
families with two affected relatives, and 3.90 in 
families with three affected relatives. The 
familial pattern of the disease provides clear 
evidence for the important role of genetic 
variation in determining risk [26]. The ratio of 
breast cancer is the highest in young people. A 
notable early achievement in the genetic 
dissection of the disease was linkage mapping, 
using breast cancer family data, of the BRCA 
and BRCA genes. Rare mutations in these genes 
confer high relative risks to carriers of 10- to 
20-fold, corresponding to a 30%–60% risk by 
the age of 60 years, compared with 3% for the 
general population [27].The possibility of an 
underlying breast cancer almost occurs at any 
age [28]. Another thing is age; the risk of 
developing breast cancer increases with age. 
Most advance cases of breast cancer commonly 
are found in elderly. Living up to age 95, about 
one in eight would be diagnosed with breast 
cancer during their lives However, the actual 
lifetime risk is lower than that, due to the fact 
that 90% of women die before age 95, mostly 
from heart attacks, strokes, or other forms of 
cancer. The possibility of breast cancer rises as 
 




getting older, but breast cancer tends to be more 
common in younger people [29, 30]. In 
addition, other factors such as diet and physical 
activity can do a lot with this type of cancer. For 
example, it has been reported that, physical 
activity can improve quality of life, decrease 
fatigue and reduce all-cause and breast cancer-
specific mortality in breast cancer survivors. 
The beneficial effects of physical activity may 
regulate circulating levels of insulin, insulin 
growth factors (IGFs) I and II and their binding 
proteins (IGFBPs), or inflammatory biomarkers 
[4]. Evidence suggests that fruits and 
vegetables, low-fat dairy products, fish, 
monounsaturated and polyunsaturated fatty 
acids, vitamin D, calcium, and phytoestrogens 
may lessen the risk of breast cancer, while high 
consumption of fried meat, saturated fatty acids 
is associated with increased risk of breast 
cancer[31 , 32]. 
Table 1: Associated risk factors with breast cancer 
Risk factors References 
Gender Women 150 33 
men 1 
Physical activity 35 
Genetic (About 5 to 10%) 36 
Dietary Alcohol 37 
Fat 38 
High fiber 39 
Hormones 40 
childbearing 12, 13 
Viruses 41 
Proliferative breast lesions 42 
 Long-term use of oral 
contraceptives 
43 
Height, Weight, Age 44 
Heritability of Mammographic 
Density (1.8 to 6.0 time) 
45 
 
Gender and Physical activity 
Breast cancer is more likely in women 
population than men. For every 150 cases of 
female breast cancer, there is one case of male 
breast cancer [33]. In developed countries, 
about 99% of breast cancer cases are diagnosed 
in women. In addition to this, white women 
aged 50 years and older have experienced 
higher prevalence rates than their non-white 
counterparts [33]. Whilst, breast cancer 
incidents in male‘s European population is one 
or less per 100 000. Male breast cancer has high 
prevalence at the age of 71 years. There are no 
randomized data giving information on the 
optimal therapy for male breast cancer patients, 
thus limiting firmer conclusions [34]. Men 
diagnosed with breast cancer are commonly 
older than women with breast cancer. They are 
more expected to be diagnosed with hormone-
receptor positive tumors, with about six out of 
seven cases being estrogen-receptor 
positive. On the whole prognosis is worse for 
men than for women [30]. Physical activity is 
an another prominent factor; there is some 
evidence from available RCTs that physical 
activity intervention may result in beneficial 
changes in insulin levels, IGFI and IGFBP, as 
well as inflammatory biomarkers in breast 
cancer survivors. However, available studies are 
generally small, and the evidence is not 
consistent. For that reason, further larger RCTs 
on physical activity and biomarkers in breast 
cancer survivors are warranted. Some studies 
show that, about 50% risk reduction in breast 
cancer death in women who engaged in 
moderate intensity physical activity before and 
after their diagnosis of breast cancer [35]. 
Genetic Factors 
Genetic and lifestyle/environmental factors are 
implicated in the etiology of breast cancer. The 
genetic factor of the disease is reflected on a 
tendency to cluster in families, even thought 
this could also reflect shared life-style and 
environment [36]. About 5 to 10% of breast 
cancer cases are associated with a hereditary 
inclination, characterized by young age at 
diagnosis and/or multiple relatives with breast, 
ovarian and/or prostate cancer [46]. The genetic 
factors known to be involved in breast cancer 
risk consist of about 30 genes [20]. Two 
autosomal dominant genes, BRCA1 on 17q21 
and BRCA2 on 13q12, make up for almost 15% 
of the cases of familial breast cancer [47, 48] 
which, loss of heterozygosity of these normal 
alleles is frequently observed [46].  
 In addition to this, women who carry a 
destructive BRCA mutation have a 60% to 80% 
risk of developing breast cancer in their 
lifetimes [49].  
On the other hand, other gens beside BRCA 
may be associated with breast cancer. For 
instance, the presence of NBR2, near breast 
cancer gene 1, has been discovered, and 
research into its contribution to breast cancer 
pathogenesis is ongoing [50]. Moreover, genetic 
variation in genes involved in estrogen 
synthesis, metabolism and signal transduction 
have been suggested to play a role. Estrogen 
influences the growth, differentiation and 
 




function of breast tissue, exerting its biological 
effect through binding to estrogen receptors 
(ERs). ERs belong to a family of transcription 
factors, the nuclear receptor super family, 
responsible for mediating the effects of steroids 
on development, reproduction, proliferation, 
cellular homeostasis and gene expression [51]. 
These estrogen gen polymorphisms are linked 
to the metabolism of carcinogens (CYP1A1, 
CYP1B1, CYP17, CYP19, COMT, NAT2, 
GSTM1, GSTP1, GSTT, . . . ), to estrogen, 
androgen and vitamin D action (ESR1, AR, 
VDR), to co-activation of gene transcription 
(AIB1), to DNA damage response pathways 
(CHEK2, HRAS1, XRCC1, XRCC3,XRCC5) 
[51]. Sequence variants of these genes that are 
relatively common in the population may be 
associated with a small to moderate increased 
relative risk for breast cancer. Combinations of 
such variants could lead to multiplicative 
effects. In addition to this, PON1 M and Q 
alleles are associated with a higher risk of breast 
cancer. Persons having MM and QQ genotypes 
have a lower level and lower detoxification 
activity of the PON1 enzyme, which may 
enhance the vulnerability of the breast to 
genetic damage by reducing the ability to 
detoxify inflammatory oxidants, as well as 
dietary carcinogens [44]. 
Dietary factors 
Alcohol 
Alcohol appears to be a risk factor for breast 
cancer in women [37]. Findings indicate that, 
among lifestyle factors, alcohol consumption is 
constantly linked to increased risk for breast 
cancer in both premenopausal and 
postmenopausal women, aside from of the kind 
of alcoholic drink consumed. The percentage of 
breast cancer attributable to alcohol 
consumption between U.S. women has a 
population attribute to the risk of 2.1%, 
accounting for about 14,000 women yearly [52]. 
One or two drinks each day increases 
the relative risk to 150% of normal, and six 
drinks per day increases the risk to 330% of 
normal The primary mechanism through which 
alcohol causes breast cancer may be by 
increasing estrogen levels [53]. 
Fat intake 
It is believed that, modification of dietary fat 
and fiber could help prevent cancers of the 
breast [38]. There is a controversially about this 
subject that, whether fat intake is related to 
breast cancer or not? For many years high 
energy intake, most of all high fat intake was 
considered the critical explanation for the 
regional differences in breast cancer incidence. 
Mainly the consumption of animal fat and 
saturated fatty acids was accused of a 
contributory association with breast cancer. 
However, some studies show that, there is not 
significant relationship between fat 
consumption and breast cancer risk. Animal fat, 
generally regarded as ‗‗unhealthy‘‘, was not 
found to be considerably related to breast cancer 
possibility [54].  
High fiber foods 
Some studies have been suggested that, a high 
consumption level of fruit and vegetables as 
healthy diet can effect against hypertension, 
obesity and coronary heart disease and even 
cancer [39]. However, according to other 
studies Brassicas vegetable intake (broccoli, 
cauliflower, cabbage, kale and Brussels sprouts) 
was inversely related to breast cancer growth. 
The relative risk among women in the highest 
decile of Brassica vegetable consumption 
(median, 1.5 servings per day) compared to the 
lowest decile (virtually no consumption) was 
0.58. That is, women who consumed around 1.5 
servings of Brassica vegetables per day had 
42% less risk of developing breast cancer than 
those who consumed virtually none [55]. In 
addition, other studies show that, the possible 
relationship of fruits and vegetables with risk of 
breast cancer has normally been much weaker 
and less reliable [56]. 
Hormones and childbearing  
Some evidences suggest that steroid hormones 
are implicated in the risk of breast cancer [40]. 
steadily increased blood levels of estrogen are 
associated with an increased risk of breast 
cancer, as are increased levels of the androgens 
androstenedione and testosterone (which can be 
directly transformed by aromatase to the 
estrogens estrone and estradiol, respectively). 
Increased blood levels of progesterone are 
associated with a decreased risk of breast cancer 
in premenopausal women [57].A number of 
circumstances which increase exposure to 
endogenous estrogens including not having 
children, delaying first childbirth, not 
breastfeeding, early menarche (the first 
menstrual period) and late menopause are 
suspected of increasing lifetime risk for 
developing breast cancer [58]. Several studies 
put forward that total breastfeeding time 
reduces breast cancer possibility. However, 
 




some other researches indicate that there is no 
significant connection between age at first 
childbirth and number of children in breast 
cancer incident [59].  
Viruses 
 Several kinds of viruses have become major 
suspects as etiological agents for human breast 
cancer. Unraveling the relationship between 
viruses and breast cancer incident is prominent 
for better understanding of its etiology, early 
detection and possibly prevention. Human 
Papilloma viruses, mouse mammary tumor 
virus and Epstein-Barr virus are the main 
candidate viruses as causes of human breast 
cancer. Human Papilloma viruses and the 
mouse mammary tumor virus have hormone 
responsive elements that appear to be associated 
with enhanced replication of these viruses in the 
presence of corticosteroid and other hormones 
[41]. Moreover, Epstein-Barr virus (EBV) 
contribution in breast carcinogenesis is still 
controversial .According to one study, by acting 
as a promoter for the development of PIBC; it 
could contribute to progression of breast cancer 
[60]. 
Molecular Pathology 
 As breast cancer is one of the heterogeneous 
diseases including clinical, morphological and 
molecular aspects, molecular biology of the 
disease is prominent to examine. This 
heterogeneity cannot be explained only by 
clinical parameters such as tumor size, lymph 
node involvement, histological grade, age; or by 
biomarkers like estrogen receptor (ER), 
progesterone receptor (PGR) and epidermal 
growth factor receptor 2 (HER2) regularly used 
in the diagnosis and treatment of patients. 
Moreover, technological breakthroughs and in 
particular high throughput approaches like 
proteomics technology [61], have allowed 
scientists to investigate deeply in the nature of 
breast cancer which shows that, there is a 
systematic interconnection of several signaling 
pathways and that both the cellular 
microenvironment, and the innate 
characteristics of the patient influence disease 
pathophysiology, outcome and treatment 
response. These findings indicate that, there 
might be more than one disease relating to 
breast cancer, and that each patient entails a 
particular case where personalized medicine 
could play a key role in treatment strategy [62, 
63].  
Metastasis 
The risk of developing distant metastatic may 
remain after management of the primary tumor. 
Despite advances in surgery, chemotherapy and 
radiation therapy, breast cancer still lacks 
effective treatment, and it might not be 
controlled in preventing relapses. In addition, 
they are the most lethal form of breast cancer 
relapses and are associated with a high rate of 
mortality, and increased costs for care [64]. 
Mortality is approximately invariably due to 
metastasis. For instance, among 25% and 50% 
of patients diagnosed with breast cancer will 
ultimately develop deadly metastases, 
frequently decades after the time of diagnosis 
and removal of the primary tumor. The 
prognosis for patients with metastatic breast 
cancer is normally unfavorable, with an average 
5-year survival rate of only about 25% [65].The 
different histological subtypes of breast cancer 
(e.g. ductal, lobular, basal like) and molecular 
marker expression (e.g. estrogen receptor, ER; 
progesterone receptor, PR; human epidermal 
growth factor .receptor 2, HER2) have strong 
prognostic and predictive values. For example, 
triple negative breast cancers (i.e. ER-, PR-, 
HER2- negative) are associated with a 
significantly increased risk of progression and 
metastasis formation. In spite of intense clinical 
research efforts, only limited advances have 
been obtained in the management of breast 
cancer metastases. Lymphatic organs are pro of 
metastasis. The HER2 gene encodes the 
receptor tyrosine kinase HER2 and is often 
over-expressed or amplified in breast cancer. 
Up-regulation of HER2 contributes to tumor 
progression. In fact, HER2 plays a role in 
increasing proliferation and survival of the 
primary tumor and distant lesions which upon 
completion of full transformation cause 
metastases [66]. 
Treatment strategies 
 Different strategies may be use in treating 
breast cancer. The first strategy is to eradicate 
of established metastases by adding novel 
modalities to current treatments, such as 
immunotherapy or targeted therapies. A second 
way is to prevent tumor cell dissemination to 
secondary organs by targeting specific steps 
leading the metastatic cascade and organ-
specific tropism. A third one is to block the 
colonization of secondary organs and 
subsequent cancer cell growth by impinging on 
the ability of distributed cancer cells to adapt to 
the novel microenvironment. To achieve the 
 




best results it could be necessary to unite these 
strategies. These advances entail a deeper 
understanding of the specific genetic events 
occurring in cancer cells and of the host 
responses that co-operate to promote metastasis 
formation. In particular the crosstalk between 
disseminated cancer cells and the host 
microenvironment is emerging as a critical 
determinant of metastasis. Therefore, the 
identification of tissue-specific signals involved 
in metastatic progression will open the way to 




As breast cancer is one of the most common 
cancers among women over the world [68], so 
there should be more accurate therapy for it. To 
achieve this goal, deep examination of this 
disease is highly needed. Therefore, molecular 
biology studies of this disorder could be 
possibly helpful due to its potential for bringing 
a deep insight of the illness. 
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